Form 4: Insulet SVP Awarded Equity and Stock Options

Insulet Corporation's SVP of Regulatory, Quality & Compliance, Laetitia Cousin, received an annual restricted stock unit award and non-qualified stock options.

Summary

• Laetitia Cousin, SVP, Regulatory, Quality & Compliance at Insulet Corp (PODD), was granted 1,044 shares of common stock as a Restricted Stock Unit (RSU) award on February 24, 2026.
• The RSU award vests in substantially equal installments on the first, second, and third anniversaries of the grant date, settling in shares on a one-for-one basis.
• On February 25, 2026, 111 shares of common stock were disposed of at a price of $248.12 per share to cover tax obligations associated with the vesting of restricted stock units.
• Following the disposition, the beneficial ownership of common stock is 5,927 shares.
• An annual Non-Qualified Stock Option (Option) Award for 2,718 derivative securities was granted on February 24, 2026, with an exercise price of $245.25.
• These options become exercisable in substantially equal installments on the first, second, third, and fourth anniversaries of the grant date and expire on February 24, 2036.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive event, reflecting standard executive compensation practices that align management incentives with long-term company performance, without indicating any significant operational or financial changes.

Positives

• The grant of 1,044 Restricted Stock Units (RSUs) aligns the executive's interests with long-term shareholder value.
• The award of 2,718 Non-Qualified Stock Options provides an incentive for future performance and potential capital appreciation for the executive.

Negatives

• The disposition of 111 shares to cover tax obligations reduces the immediate beneficial ownership of common stock, which is a standard practice for equity compensation.

Future Outlook

The executive's equity awards are structured with future vesting schedules, indicating a long-term incentive plan. The Restricted Stock Units will vest over three years, and the Non-Qualified Stock Options will vest over four years, aligning future compensation with sustained company performance.

Industry Context

StockSavvy.ai notes that executive compensation packages frequently include a mix of cash, restricted stock units, and stock options. This structure is common in the medical device and healthcare technology sectors, aiming to incentivize long-term performance and align management interests with shareholder returns. Such routine equity grants are a standard component of executive remuneration strategies across the industry.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) and Non-Qualified Stock Options as part of executive compensation is a common practice across the S&P 500 and particularly within the medical technology sector, similar to companies like Medtronic (MDT) or Dexcom (DXCM).
• The vesting schedules (3 years for RSUs, 4 years for options) are typical for long-term incentive plans, designed to retain executives and encourage sustained performance, comparable to industry benchmarks.

Stakeholder Impact

• Shareholders: The equity awards are designed to align the executive's interests with long-term shareholder value, potentially leading to improved performance and stock appreciation.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The Restricted Stock Units will vest in substantially equal installments on the first, second, and third anniversaries of the grant date (February 24, 2026).
• The Non-Qualified Stock Options will become exercisable in substantially equal installments on the first, second, third, and fourth anniversaries of the grant date (February 24, 2026).

Key Dates

Keywords

Insulet Corp, PODD, Form 4, Insider Transaction, Restricted Stock Units, RSU, Stock Options, Executive Compensation, Equity Award, Insider Ownership